Gilead Sciences (GILD) Receivables (2009 - 2026)

Gilead Sciences has reported Receivables for 18 years, with the latest figure at $5.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 13.6% year-over-year to $5.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (up 13.6% YoY), and the FY2025 full-year result was $6.5 billion, up 38.9% from the prior year.
• Receivables for Q1 2026 stood at $5.3 billion, down from $6.5 billion in the prior quarter.
• The five-year high for Receivables was $6.5 billion in Q4 2025, with the low at $3.9 billion in Q1 2022.
• Historically, Receivables has averaged $4.9 billion across 5 years, with a median of $4.8 billion in 2023.
• The largest YoY upside for Receivables was 38.9% in 2025 against a maximum downside of 17.13% in 2025.
• Gilead Sciences' Receivables stood at $5.6 billion in 2022, then fell by 15.23% to $4.8 billion in 2023, then fell by 1.67% to $4.7 billion in 2024, then jumped by 38.9% to $6.5 billion in 2025, then slipped by 18.3% to $5.3 billion in 2026.
• The last three Receivables figures came in at $5.3 billion (Q1 2026), $6.5 billion (Q4 2025), and $5.8 billion (Q3 2025), per Business Quant data.